Lilly, Innovent Form Collaboration for Oncology and Immunology Candidates
Eli Lilly and Innovent Biologics have entered a strategic collaboration to advance novel oncology and immunology candidates, granting Lilly exclusive global rights outside China while Innovent retains commercialization in Greater China. The agreement launches preclinical work immediately and sets a path toward early clinical trials.
1. Agreement Overview
Eli Lilly and Innovent Biologics have established a strategic alliance to co-develop novel oncology and immunology therapies, targeting two early-stage candidates and combining Lilly’s global development infrastructure with Innovent’s research capabilities.
2. Roles and Responsibilities
Under the deal, Lilly will fund all research and development, lead regulatory filings and handle commercialization in markets outside Greater China, while Innovent will conduct preclinical activities and retain exclusive rights to commercialize in Greater China, sharing in milestone payments.
3. Development Pathway
The collaboration kicks off preclinical studies immediately, with both partners aiming to file Investigational New Drug applications and initiate Phase I clinical trials as soon as regulatory clearances are obtained, expediting entry into human testing.